On Sept. 7, 2010, Bristol-Myers Squibb acquired ZymoGenetics for $9.75 per share or $885 million in cash. In 2008, ZymoGenetics received FDA authorization to manufacture the product Thrombin topical (Recombinant) which is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.

Zymo was founded in 1981 by University of Washington professors Earl Davie and Benjamin Hall, and Nobel award winning University of British Columbia professor Michael Smith.